Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Blue Zones and Marshall Join Forces to Help Transform the Health of El Dorado Hills
Marshall has launched Blue Zones Ignite, a new community initiative focused on improving well-being and making healthy living more accessible in El Dorado Hills. The program applies proven strategies to help people make healthier choices in the environments where they live, work, and spend the majority of their time. The initiative will begin with a readiness and feasibility study from September 16 to 18, aiming to explore how the area can be made healthier for people of all ages.
NorthStar Medical Technologies Appoints Jon Coulter as Non-Executive Chairman
NorthStar Medical Technologies, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced the appointment of Mr. Jon Coulter as Non-Executive Chairman. Mr Coulter has been a Board Member of NorthStar since 2010 and was appointed to the post effective March 26, 2025. He succeeds Mr. Stephen Merrick, who joined NorthStar in 2016, has served as Executive Chairman since July 2023 and is now retiring from that position.
xCures Achieves Fully Functional IAS Solution
xCures, a leader in artificial intelligence (AI)-powered healthcare data solutions, announced the launch of its fully operational Individual Access Services (IAS) within the Trusted Exchange Framework and Common Agreement (TEFCA), marking a major step toward seamless, nationwide patient data access.
AC Health, ABC Impact Partner to Transform Filipino Health
AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore-based impact investor dedicated to Asia and backed by Temasek Trust and Temasek. This strategic investment marks ABC Impact’s entry into the Philippine healthcare sector, expanding its regional footprint.
Novartis Ianalumab Trials Succeed in Sjögren’s Disease
Novartis announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren’s disease. Both trials met the primary endpoint of demonstrating statistically significant improvements in disease activity. These results support the potential for ianalumab, a drug with a dual mechanism of action, B-cell depletion and BAFF-R inhibition, to become the first targeted treatment for patients with Sjögren’s disease, a chronic, disabling autoimmune disease.
To share your insights, please write to us at sudipto@intentamplify.com
